Starpharma Holdings (ASX:SPL) Interest Expense (Positive)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:SPL Starpharma Holdings Ltd ASX:SPL
51 GF Score
Price A$0.73
GF Value A$0.44
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Starpharma Holdings Interest Expense (Positive)?

Interest Expense (Positive) only applies to insurance companies.

ASX:SPL
51GF Score
Starpharma Holdings Ltd ASX:SPL
Interest Expense (Positive) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Starpharma Holdings (ASX:SPL) Overvalued in 2026?

Based on GuruFocus' analysis, Starpharma Holdings stock appears to be overvalued. The current stock price of A$0.73 is trading 65.9% above its estimated GF Value™ of A$0.44. GuruFocus considers Starpharma Holdings to be Significantly Overvalued.

Key valuation signals for ASX:SPL:

  • Interest Expense (Positive):
  • GF Value™: A$0.44 vs. price of A$0.73 (65.9% above fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the ASX:SPL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Starpharma Holdings Business Description

Address 4-6 Southampton Crescent, Abbotsford, Melbourne, VIC, AUS, 3067
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating, and VIRALEZE, an antiviral nasal spray.
51GF Score

Get the complete analysis for ASX:SPL

Interest Expense (Positive) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.73
Price
A$0.44
GF Value